The Protective Effect of Losartan on Diabetic Neuropathy in a Diabetic Rat Model

Abstract

Aim: Involvement of the peripheral and autonomic nervous systems is possibly the most frequent complication of diabetes. Important risk factors included hyperglycemia, dyslipidemia, hypertension, and smoking. Angiotensin-converting-enzyme inhibitor (ACE) inhibitors should be beneficial in all vascular beds, including neuropathy and retinopathy. In this study we aimed to evaluate the effect of the angiotensin receptor blocker losartan on diabetic neuropathy in a diabetic rat model.

Material and Methods: 24 male, Sprague Dawley albino mature rats were divided into 3 groups; (1) control group: No drug was administered to the remainder of rats which blood glucose levels were under 120 mg/dl, (2) diabetic control: rats were given no medication, but 4 ml per day of tap water was given by oral gavage, (3) losartan groups: rats were given 10 mg/kg/day oral of losartan for 4 weeks. Electromyography (EMG) was applied to anesthetized rats at the end of 4^th weekend. Then, the animals were euthanized and sciatic nerve was performed for histopathological examination.

Results: Compound Muscle Action Potential (CMAP) amplitude of diabetic rats receiving the Saline in the EMG was significantly reduced when compared to the control group. Distal latency value and CMAP duration of diabetic rats receiving the saline were meaningfully increased when compared to the control group. CMAP amplitude and CMAP duration of diabetic rats receiving the Losartan treatment in the EMG were meaningfully reduced when compared to diabetic rats receiving the Saline.

Perineural thickness in the rats receiving the Losartan treatment was found to be significantly reduced when compared to the group receiving the Saline.

Conclusions: As a result, it has been shown in this study that perineural thickness of the Losartan treatment was significantly reduced when compared to saline receiving group, significantly increased the immunoexpression of NGF, and also provided a significantly recovery in EMG when compared to Saline receiving group.

Key words

medicine - losartan - diabetes - electromyography - histopathological

• References

• 1 Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
• 2 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
• 3 Vincent AM, Callaghan BC, Smith AL et al. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nature Reviews Neurology 2011; 7: 573-583
• 4 Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006; 1: 34-41
• 5 Dyck PJ, Davies JL, Wilson DM et al. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22: 1479
• 6 Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 1997; 2: S101
• 7 Tesfaye S, Chaturvedi N, Eaton SE et al., EURODIAB Prospective Complications Study Group . Vascular Risk Factors and Diabetic Neuropathy. N Engl J Med 2005; 352: 341-350
• 8 Cameron NE, Eaton SE, Cotter MA et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-1988
• 9 Tesfaye S, Harris N, Jakubowski JJ et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993; 36: 1266-1274
• 10 Eaton SE, Harris ND, Ibrahim S et al. Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy. Diabetologia 2003; 46: 934-939
• 11 Malik RA, Williamson S, Abbott C et al. Effect of ACE inhibitor trandolapril on human diabetic neuropathy: randomized double blind control trial. Lancet 1998; 352: 1978-1981
• 12 Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31
• 13 Ellis MI, Patterson JH. A new class of antihypertensive therapy. Angiotensin II receptor antagonists. Pharmacotherapy 1996; 16: 849-860
• 14 Rivlin AS, Tator CH. Objective clinical assesment of motor function after experimental spinal cord injury in the rat. J neurosurg 1977; 47: 577-581
• 15 Kelkar P. Diabetic Neuropathy. Semin Neurol 2005; 25: 168-173
• 16 Habib AA, Brannagan TH. Therapeutic Strategies for Diabetic Neuropathy. Current Neurology and Neuroscience Reports 2010; 10: 92-100
• 17 Lewis EJ, Hunsicker LG, Clarke WR et al. , Collaborative Study Group . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
• 18 Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
• 19 Mogensen CE. The reno-protective role of AT(1)-receptor blockers. J Hum Hypertens 2002; 3: S52-S58
• 20 Papademetriou V. The potential role of AT1-receptor blockade in the prevention and reversal of atherosclerosis. J Hum Hypertens 2002; 16: S34-S41
• 21 Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002; 13: 505-512
• 22 Lopez-Jaramillo P, Casas JP. Blockade of endothelial enzymes: new therapeutic targets. J Hum Hypertens 2002; 16: S100-S103
• 23 Ruddy MC. Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens 2002; 15: 468-471
• 24 Lewis EJ. The Role of Angiotensin II Receptor Blockers in Preventing the Progression of Renal Disease in Patients with type 2 Diabetes. Am J Hypertension 2002; 10: 123S-128S
• 25 Weir MR. Microalbuminuria as a cardiovascular and renal risk factor in patients with type 2 diabetes. Am J Clin Proc 2002; 3: 7-14
• 26 Parving H. Angiotensin II receptor blockade in the prevention of diabetic nephropathy. Am J Clin Proc 2002; 3: 21-26
• 27 Manschot SM, Gispen WH, Kappelle LJ et al. Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor. Diabetes Metab Res Rev 2003; 19: 469-477
• 28 Malik RA, Williamson S, Abbott C et al. Effect of angiotensin-converting- enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981
• 29 Reja A, Tesfaye S, Harris ND et al. Is ACE inhibition with lisinopril helpful in diabetic neuropathy?. Diabetic Med 1995; 12: 307-309
• 30 Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetics rats. Diabetologia 1992; 35: 12-18
• 31 Maxfield EK, Cameron NE, Cotter MA et al. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993; 12: 1230-1237
• 32 Aggarwal M, Singh J, Sood S et al. Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats. Methods Find Exp Clin Pharamacol 2001; 23: 131-134
• 33 Coppey LJ, Davidson EP, Rinehart TW et al. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006; 55: 341-348
• 34 Levi-Montalcini R. Tissue and nerve growth promoting factors. Biological aspects of specific growth promoting factors. Proc R Soc Med 1965; 58: 357-360
• 35 Freund V, Frossard N. Expression of nerve growth factor in the airways and its possible role in asthma. Prog Brain Res 2004; 146: 335-346
• 36 Althaus HH. Remyelination in multiple sclerosis: a new role for neurotrophins? Prog. Brain Res 2004; 146: 415-432
• 37 Chaldakov GN, Fiore M, Stankulov IS et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease. Prog Brain Res 2004; 146: 279-289
• 38 Manni L, Nikolova V, Vyagova D et al. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 2005; 102: 169-171
• 39 Hui L, Yuan J, Ren Z et al. Nerve growth factor reduces apoptotic cell death in rat facial motor neurons after facial nerve injury. Neurosciences 2015; 20: 65-68
• 40 Lu XM, Shu YH, Qiu CH et al. Protective effects and anti-apoptotic role of nerve growth factor on spinal cord neurons in sciatic nerve-injured rats. Neurol Res 2014; 36: 814-823
• 41 Shamsaei G, Madjdinasab N, Shahbazian HB et al. The Effect of Enalapril, an Angiotensin Converting Enzyme Inhibitor, on Diabetic Neuropathy: A Double Blind Random – Allocated Study. Iranıan journal of diabetes and obesity 2011; 3: 60-44